Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gen3017
- Development stage
- Discontinued
- Lead developer
- Genmab
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
GEN3017 is a humanized IgG1 bispecific monoclonal antibody developed for the treatment of relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma. It is designed to simultaneously bind CD3 on T cells and CD30 on tumor cells. By bringing T cells into close proximity with CD30-expressing lymphoma cells, GEN3017 aims to facilitate immune-mediated killing of cancerous lymphocytes. The drug was administered subcutaneously in clinical trials targeting patients with relapsed or refractory forms of these lymphomas. Development was led by Genmab[1][4][5]. As of early 2025, development for both Hodgkin's disease and non-Hodgkin's lymphoma has been discontinued at Phase 1/2[4].
- Other names
- Anti-CD3 anti-CD30 bispecific antibodyAnti-CD-3 anti-CD30 bispecific antibodyAnti-CD 3 anti-CD30 bispecific antibodyDuoBody-CD3xCD30DuoBody-CD-3xCD30DuoBody-CD 3xCD30
02
Targets
CD3 (T-cell surface glycoprotein CD3)CD30 (CD30 antigen)
Beyond the preview
Go deeper on gen3017.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gen3017.